Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Sponsor: Samsung Medical Center
Summary
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.
Official title: Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-02-01
Completion Date
2027-09-01
Last Updated
2026-08-20
Healthy Volunteers
No
Interventions
SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.
Locations (1)
Samsung Medical Center
Seoul, Seoul, South Korea